Danuta M Skowronski1, Catharine Chambers2, Suzana Sabaiduc2, Gaston De Serres3, Anne-Luise Winter4, James A Dickinson5, Jonathan Gubbay6, Kevin Fonseca7, Hugues Charest8, Mel Krajden1, Martin Petric9, Salaheddin M Mahmud10, Paul Van Caeseele11, Nathalie Bastien12, Alireza Eshaghi4, Yan Li13. 1. British Columbia Centre for Disease Control University of British Columbia, Vancouver. 2. British Columbia Centre for Disease Control. 3. Institut national de santé publique du Québec Laval University, Québec. 4. Public Health Ontario. 5. University of Calgary. 6. Public Health Ontario University of Toronto, Ontario. 7. University of Calgary Provincial Laboratory of Public Health, Calgary, Alberta. 8. Institut national de santé publique du Québec Universite de Montréal, Québec. 9. University of British Columbia, Vancouver. 10. University of Manitoba. 11. University of Manitoba Cadham Provincial Laboratory. 12. National Microbiology Laboratory, Winnipeg, Canada. 13. University of Manitoba National Microbiology Laboratory, Winnipeg, Canada.
Abstract
BACKGROUND: Canada's Sentinel Physician Surveillance Network links genetic, antigenic, and vaccine effectiveness (VE) measures in an integrated platform of influenza monitoring, described here for the 2013-2014 influenza season of resurgent A(H1N1)pdm09 and late-season type B activity. METHODS: VE was estimated as [1 - odds ratio] × 100% and compared vaccination status between individuals who tested positive (cases) and those who tested negative (controls) for influenza virus. Vaccine-virus relatedness was assessed by genomic sequence analysis and hemagglutination inhibition assays. RESULTS: Analyses included 1037 controls (of whom 33% were vaccinated) and 663 cases (of whom 14% were vaccinated). A total of 415 cases tested positive for A(H1N1)pdm09 virus, 15 tested positive for A(H3N2) virus, 191 tested positive for B/Yamagata-lineage virus, 6 tested positive for B/Victoria-lineage virus, and 36 tested positive for viruses of unknown subtype or lineage. A(H1N1)pdm09 viruses belonged to clade 6B, distinguished by a K163Q substitution, but remained antigenically similar to the A/California/07/2009-like vaccine strain, with an adjusted VE of 71% (95% confidence interval [CI], 58%-80%). Most B/Yamagata-lineage viruses (83%) clustered phylogenetically with the prior (ie, 2012-2013) season's B/Wisconsin/01/2010-like clade 3 vaccine strain, while only 17% clustered with the current (ie, 2013-2014) season's B/Massachusetts/02/2012-like clade 2 vaccine strain. The adjusted VE for B/Yamagata-lineage virus was 73% (95% CI, 57%-84%), with a lower VE obtained after partial calendar-time adjustment for clade-mismatched B/Wisconsin/01/2010-like virus (VE, 63%; 95% CI, 41%-77%), compared with that for clade-matched B/Massachusetts/02/2012-like virus (VE, 88%; 95% CI, 48%-97%). No A(H3N2) viruses clustered with the A/Texas/50/2012-like clade 3C.1 vaccine strain, and more than half were antigenically mismatched, but sparse data did not support VE estimation. CONCLUSIONS: VE corresponded with antigenically conserved A(H1N1)pdm09 and lineage-matched B/Yamagata viruses with clade-level variation. Surveillance linking genotypic, phenotypic, and epidemiologic measures of vaccine-virus relatedness and effectiveness could better inform predictions of vaccine performance and reformulation.
BACKGROUND: Canada's Sentinel Physician Surveillance Network links genetic, antigenic, and vaccine effectiveness (VE) measures in an integrated platform of influenza monitoring, described here for the 2013-2014 influenza season of resurgent A(H1N1)pdm09 and late-season type B activity. METHODS: VE was estimated as [1 - odds ratio] × 100% and compared vaccination status between individuals who tested positive (cases) and those who tested negative (controls) for influenza virus. Vaccine-virus relatedness was assessed by genomic sequence analysis and hemagglutination inhibition assays. RESULTS: Analyses included 1037 controls (of whom 33% were vaccinated) and 663 cases (of whom 14% were vaccinated). A total of 415 cases tested positive for A(H1N1)pdm09 virus, 15 tested positive for A(H3N2) virus, 191 tested positive for B/Yamagata-lineage virus, 6 tested positive for B/Victoria-lineage virus, and 36 tested positive for viruses of unknown subtype or lineage. A(H1N1)pdm09 viruses belonged to clade 6B, distinguished by a K163Q substitution, but remained antigenically similar to the A/California/07/2009-like vaccine strain, with an adjusted VE of 71% (95% confidence interval [CI], 58%-80%). Most B/Yamagata-lineage viruses (83%) clustered phylogenetically with the prior (ie, 2012-2013) season's B/Wisconsin/01/2010-like clade 3 vaccine strain, while only 17% clustered with the current (ie, 2013-2014) season's B/Massachusetts/02/2012-like clade 2 vaccine strain. The adjusted VE for B/Yamagata-lineage virus was 73% (95% CI, 57%-84%), with a lower VE obtained after partial calendar-time adjustment for clade-mismatched B/Wisconsin/01/2010-like virus (VE, 63%; 95% CI, 41%-77%), compared with that for clade-matched B/Massachusetts/02/2012-like virus (VE, 88%; 95% CI, 48%-97%). No A(H3N2) viruses clustered with the A/Texas/50/2012-like clade 3C.1 vaccine strain, and more than half were antigenically mismatched, but sparse data did not support VE estimation. CONCLUSIONS: VE corresponded with antigenically conserved A(H1N1)pdm09 and lineage-matched B/Yamagata viruses with clade-level variation. Surveillance linking genotypic, phenotypic, and epidemiologic measures of vaccine-virus relatedness and effectiveness could better inform predictions of vaccine performance and reformulation.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Sarah A Buchan; Stephanie Booth; Allison N Scott; Kimberley A Simmonds; Lawrence W Svenson; Steven J Drews; Margaret L Russell; Natasha S Crowcroft; Mark Loeb; Bryna F Warshawsky; Jeffrey C Kwong Journal: JAMA Pediatr Date: 2018-09-04 Impact factor: 16.193
Authors: Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia Journal: JAMA Netw Open Date: 2018-10-05
Authors: Manjusha Gaglani; Jessica Pruszynski; Kempapura Murthy; Lydia Clipper; Anne Robertson; Michael Reis; Jessie R Chung; Pedro A Piedra; Vasanthi Avadhanula; Mary Patricia Nowalk; Richard K Zimmerman; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Suzanne E Ohmit; Arnold S Monto; Huong Q McLean; Edward A Belongia; Alicia M Fry; Brendan Flannery Journal: J Infect Dis Date: 2016-01-06 Impact factor: 7.759
Authors: Brendan Flannery; Richard K Zimmerman; Larisa V Gubareva; Rebecca J Garten; Jessie R Chung; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Suzanne E Ohmit; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Pedro A Piedra; Vasiliy P Mishin; Anton P Chesnokov; Sarah Spencer; Swathi N Thaker; John R Barnes; Angie Foust; Wendy Sessions; Xiyan Xu; Jacqueline Katz; Alicia M Fry Journal: J Infect Dis Date: 2016-05-06 Impact factor: 7.759